Merck Sprints Toward Late 2020 Filing For Pneumococcal Vaccine V114

Company Is Catching Up With Pfizer’s Planned Q4 Submission Of 20vPnC

 
• By Mandy Jackson

Merck’s 15-valent vaccine candidate was non-inferior to Pfizer’s Prevnar 13 in a Phase III study and provided superior protection against serotype 3, a frequent cause of invasive pneumococcal disease. 

group of cyclist at professional race
Merck is racing ahead with a competitor to Prevnar 13 and Pfizer's 20-valent vaccine candidate • Source: Shutterstock

More from Clinical Trials

More from R&D